Clinical trial
An International Study of the Safety and Tolerability of Corlux for Psychotic…
NCT00146523 · Corcept Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00146523 |
|---|---|
| Title | An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression |
| Official title | An International, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of CORLUX™ (Mifepristone) vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Psychotic Major Depression (PMD) |
| Lead sponsor | Corcept Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | Mifepristone, placebo |
| Enrollment | 247 |
| Start date | May 1, 2005 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Sep 7, 2005 |
| Last update posted | Feb 15, 2012 |
| Countries | Bulgaria, Croatia, Romania, Serbia and Montenegro |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: